Can You Still Get Compounded Semaglutide in 2026? Current FDA Status

Compounded semaglutide is no longer a freely-available product in the United States. The FDA declared the semaglutide shortage resolved on February 21, 2025^[1], and the enforcement-discretion windows that had let pharmacies compound it during the 2022–2024 shortage have closed: February 21, 2025 ended new supply for most channels, with 503A state-licensed pharmacies given until April 22, 2025 and 503B outsourcing facilities until May 22, 2025 to stop^[2]. Patient-specific 503A compounding remains legally available under a narrow exception — the prescriber must document a clinical need that FDA-approved Wegovy, Ozempic, or Rybelsus cannot meet for that specific patient — but “cheaper” is explicitly not a qualifying reason. This is what changed, what is still allowed, and what cash-pay patients on compounded semaglutide should do next.

The honest summary

• Semaglutide is off the FDA shortage list. The FDA's February 21, 2025 determination found that Novo Nordisk's supply could meet projected national demand, ending the shortage that had legally permitted large-scale compounding^[1].
• 503B mass-batch compounding is now enforcement-prioritized. Outsourcing facilities had until May 22, 2025 to stop compounding semaglutide from bulk drug substance. After that date the FDA can — and does — issue warning letters and take enforcement action against 503B facilities that continue^[2].
• 503A patient-specific compounding survives, narrowly. A state-licensed 503A pharmacy can still compound semaglutide for an individually-identified patient if the prescriber documents that the FDA-approved product is not medically appropriate for that patient — for example a documented allergy to an excipient in commercial Wegovy, or a strength not commercially available^[3]. Cost, supply convenience, and prescriber preference do not satisfy the standard.
• Cash-pay branded access has changed the economics. Novo Nordisk's NovoCare Pharmacy ships Wegovy at $349/month for all maintenance doses, with a $199 introductory offer through June 30, 2026^[5]. The cash-pay gap between compounded and branded semaglutide that drove the 2023–2024 market is much narrower in 2026.
• The door is being shut permanently. FDA's April 30, 2026 proposed rule would formally exclude semaglutide, tirzepatide, and liraglutide from the section 503B Bulks List on a finding of no clinical need^[4] — meaning even a future return to shortage would not automatically re-open outsourcing-facility compounding of semaglutide.

Timeline: how we got here

• 2022. FDA added semaglutide injection to the drug shortage list as Wegovy and Ozempic demand outstripped supply, opening the door for 503A and 503B compounding of the molecule.
• February 21, 2025. FDA announced that the semaglutide shortage was resolved, finding that Novo Nordisk's supply met national demand^[1]. Differentiated enforcement-discretion windows attached for 503A and 503B compounders.
• April 22, 2025. The 503A enforcement-discretion window closed. After this date, state-licensed pharmacies compounding semaglutide outside the patient-specific clinical-need exception are subject to FDA enforcement^[2].
• May 22, 2025. The 503B enforcement-discretion window closed. From this date forward FDA may take enforcement action against outsourcing facilities that continue to compound semaglutide from bulk drug substance^[2].
• April 30, 2026. FDA published a proposed rule to formally exclude semaglutide, tirzepatide, and liraglutide from the section 503B bulks list, on the basis that the agency identified no clinical need for outsourcing facilities to compound these substances from bulk^[4]. Public comment is open through June 29, 2026.

503A vs 503B: why the distinction matters

The Federal Food, Drug, and Cosmetic Act creates two compounding regimes^[3]. Understanding which one a pharmacy operates under explains why some telehealth platforms stopped shipping compounded semaglutide in 2025 and others still claim they can.

• 503A pharmacies are traditional state-licensed compounders. They may compound a drug for an individually-identified patient pursuant to a valid prescription. With semaglutide off the shortage list, a 503A pharmacy can only lawfully compound it when the prescriber documents a clinical difference that the commercial product cannot meet for that specific patient — not for cost or convenience.
• 503B outsourcing facilities register with the FDA to compound larger batches without patient-specific prescriptions, but may only compound from bulk drug substances on FDA's 503B Bulks List (or that appear on the shortage list). Semaglutide is on neither, and the April 2026 proposed rule would keep it off the bulks list permanently^[4].

So can you still buy compounded semaglutide?

Short answer: sometimes, legitimately, but only through a 503A pharmacy for a patient with a documented clinical need — and many platforms that advertised cheap compounded semaglutide during the shortage have either stopped, switched patients to branded products, or moved to personalized-dose formulations. If a website is still selling mass-market compounded semaglutide at shortage-era prices with no clinical-need documentation, that is exactly the kind of operation FDA is now targeting^[6], and several have received warning letters. If you are shopping, see where to buy semaglutide safely, our best compounded semaglutide providers, and the cheapest GLP-1 without insurance buyer guide.

• Legitimate path that survives: a 503A pharmacy compounding for you specifically because a licensed prescriber documented that Wegovy/Ozempic/Rybelsus is not appropriate (e.g. excipient allergy, or a customized strength). This is real but narrow.
• What to be wary of: "research-use-only" semaglutide, sites with no licensed prescriber or consultation, and any vendor that frames the discount — not a clinical reason — as the basis for compounding. Compounded drugs are not FDA-approved and are not evaluated for safety, effectiveness, or quality^[6].
• How to verify a provider: confirm a licensed U.S. prescriber reviews your case, the pharmacy is state-licensed (503A) or FDA-registered (503B), and ideally that it holds LegitScript certification or PCAB accreditation.

What cash-pay patients should do now

• Re-run the branded math. Novo Nordisk's NovoCare Pharmacy offers Wegovy at $349/month cash pay (all maintenance doses), with a $199 introductory price on the first fills through June 30, 2026^[5]. For many patients the compounded-vs-branded savings that justified the risk in 2023 are now small.
• Check insurance first. If your plan covers Wegovy or Ozempic, that pathway is almost always cheaper than cash-pay compounded.
• Ask your provider exactly which pathway they are using. Branded via cash pay or insurance; 503A patient-specific compounded semaglutide with documented clinical need; oral Rybelsus; or a switch to tirzepatide. A provider who cannot answer this clearly is one to re-evaluate.

How this differs from compounded tirzepatide

The two molecules are on closely parallel but not identical tracks. Tirzepatide came off the shortage list first (October 2, 2024), and its enforcement windows — February 18, 2025 (503A) and March 19, 2025 (503B) — closed about two months ahead of semaglutide's. Tirzepatide's resolution also ran through the Outsourcing Facilities Association v FDA litigation, in which the court denied a preliminary injunction on March 5, 2025. The April 30, 2026 proposed 503B bulks-list exclusion covers both molecules plus liraglutide^[4]. See our companion explainer on the current FDA status of compounded tirzepatide for that timeline, and which GLP-1s can still be compounded.